NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, Price Target & More

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals declared that its Board of Directors has authorized a stock buyback program on Thursday, August 10th 2017, which authorizes the company to buyback $20,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 2.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its stock is undervalued.

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) announced its quarterly earnings data on Wednesday, May, 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.13. The firm had revenue of $58.40 million for the quarter, compared to analyst estimates of $60.75 million. Amphastar Pharmaceuticals had a positive return on equity of 3.39% and a negative net margin of 1.50%. The company's quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the company posted $0.09 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

6 equities research analysts have issued 1-year price objectives for Amphastar Pharmaceuticals' shares. Their forecasts range from $18.00 to $26.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $21.20 in the next year. This suggests a possible upside of 25.4% from the stock's current price. View Analyst Ratings for Amphastar Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Amphastar Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Horizon Pharma (HZNP), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Endo International (ENDP) and Spectrum Pharmaceuticals (SPPI).

News headlines about AMPH stock have trended somewhat positive on Saturday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a daily sentiment score of 0.06 on Accern's scale. They also gave news stories about the company an impact score of 45.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Amphastar Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.28%) and Municipal Employees Retirement System of Michigan (0.02%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

AMPH stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Diane G Gerst, Floyd F Petersen, Jason B Shandell, Michael A Zasloff, Richard K Prins, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AMPH stock can currently be purchased for approximately $16.90.

Amphastar Pharmaceuticals has a market capitalization of $775.66 million and generates $240.18 million in revenue each year. The company earns $4.50 million in net income (profit) each year or $0.38 on an earnings per share basis. Amphastar Pharmaceuticals employs 1,644 workers across the globe.

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]